Yervoy

Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
FDA expands Opdivo use for metastatic melanomaFDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with metastatic melanoma.
Huge coalition to advance cancer treatments
FDA expands use of melanoma drugThe FDA this week expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma - lowering the risk that melanoma will return following surgery.
First 2-drug combo for advanced melanoma, plus 5 more FDA actionsFirst 2-drug therapy approved for advanced melanoma and four other recent approvals by FDA relating to new drugs and treatments.
Oncology drugs in the pipelineSeveral new drugs hold promise, but cost is a top concern.
[BLOG]: Promising late-stage melanoma pipeline to evolve treatment algorithmMelanoma, an aggressive disease with a rapidly rising incidence rate, presents the oncology field with some of its greatest challenges and opportunities. Long considered one of the most difficult diseases to treat with pharmacotherapy, drug development within melanoma has lagged behind that of many other cancers, culminating in decades of limited progress. Developments in molecular biology, however, have led to an increased understanding of the molecular heterogeneity of melanoma in recent years, which has resulted in new insights into the roles of oncogenes, signaling pathways, immune checkpoints, and tumor-promoting events, accelerating the rate of discovery of therapeutic targets.
ASCO: Ipilimumab improves recurrence-free survival in melanomaIpilimumab (Yervoy, Bristol-Myers Squibb) significantly improved recurrence-free survival in patients with stage 3 melanoma in the adjuvant setting, compared to placebo, according to data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Combination therapy for melanoma promising in early trialResults of a phase 1b trial of nivolumab combined with ipilimumab demonstrated one- and two-year survival rates of 94 and 88 percent, respectively, in patients with advanced melanoma.
Targeted drugs lengthen survival for melanoma patientsThough a cure for melanoma remains elusive, continued research has borne several promising treatment approaches with more targeted drugs that can help lengthen melanoma patients' survival, buying them time until more effective treatments come to light.